ライフサイエンスコーパス: late gadolinium enhancement

1 tor of 6-month wall thickening compared with late gadolinium enhancement.

2 enhancement and edema exceeding the area of late gadolinium enhancement.

3 ion by LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement.

4 ipants, 114 had a visible myocardial scar by late gadolinium enhancement.

5 ) and showed intramyocardial and pericardial late gadolinium enhancement.

6 sudden death risk factors and 50 (37%) with late gadolinium enhancement.

7 No subjects had late gadolinium enhancement.

8 sment of myocardial perfusion, function, and late gadolinium enhancement.

9 Viability was assessed using late gadolinium enhancement.

10 n (r=0.37-0.47) but not with the presence of late gadolinium enhancement.

11 characterization of replacement fibrosis by late gadolinium enhancement.

12 T2-prepared steady-state-free precession, or late gadolinium enhancement.

13 rosis was identified by a diffuse pattern of late gadolinium enhancement.

14 t of dyskinetic area, and score of extent of late gadolinium enhancement.

15 y T1 mapping, rest first pass perfusion, and late gadolinium enhancement.

16 haracterisation with a suggestive pattern of late gadolinium enhancement.

17 Microvascular obstruction was assessed with late gadolinium enhancement.

18 77.8% (14/18) of patients had focal late gadolinium enhancement.

19 o subjects in groups 3 and 4 had evidence of late gadolinium enhancement.

20 bal distribution is not well visualized with late gadolinium enhancement.

21 d with those of other cardiac MR parameters (late gadolinium enhancement, 0.90; T2 ratio, 0.79; extra

22 proportion of total left ventricular mass (%late gadolinium enhancement; 10.4+/-13.2% versus 8.5+/-8

23 correlating with the presence or absence of late gadolinium enhancement (1001+/-82 versus 891+/-38 m

24 y larger than the infarct size quantified by late gadolinium enhancement (37.2+/-11.6% versus 22.3+/-

25 atients without and in patients with evident late gadolinium enhancement (466 msec +/- 14, 406 msec +

26 ubset of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index

27 The presence of late gadolinium enhancement (65% versus 64%; P=0.99) and

28 FDG uptake, as well as transmural extent of late gadolinium enhancement, acutely can identify viable

29 epolarization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

30 cipants with myocardial scar determined with late gadolinium enhancement and 286 age-, sex-, and ethn

31 rdiovascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

32 cardiac amyloid by combining the presence of late gadolinium enhancement and an optimized T1 threshol

33 agnetic resonance showed regional transmural late gadolinium enhancement and edema exceeding the area

34 Both transmural extent of late gadolinium enhancement and FDG uptake on the acute

35 cular magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sar

36 ver, this zone was most commonly spared from late gadolinium enhancement and T2 abnormalities, typica

37 All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imagin

38 ith late gadolinium enhancement (ventricular late gadolinium enhancement) and diffuse fibrosis with p

39 aging was performed to quantify regional (by late-gadolinium enhancement) and diffuse (by T1 mapping)

40 CMR DENSE, late gadolinium enhancement, and electrical timing toget

41 with presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricu

42 enosine stress/rest perfusion, cine imaging, late gadolinium enhancement, and magnetic resonance coro

43 nd adenosine stress perfusion, cine imaging, late gadolinium enhancement, and MR coronary angiography

44 cine, strain imaging by myocardial tagging, late gadolinium enhancement, and native T1 mapping (Shor

45 was performed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping.

46 Spatial associations among stress perfusion, late gadolinium enhancement, and T2 imaging were made at

47 Cine, stress perfusion, late gadolinium enhancement, and T2-weighted imaging tec

48 ic myocardial velocities, scar determined by late gadolinium enhancement, and wall motion abnormaliti

49 ad higher troponin T peak (P<0.0001), larger late gadolinium enhancement area (P<0.0001), and lower l

50 higher troponin T peak (P=0.006) but similar late gadolinium enhancement area (P=0.24) compared with

51 05), and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared with 14% in HTN

52 parisons of HCM subjects without evidence of late gadolinium enhancement, as well as of hypertensive

53 ardiac magnetic resonance imaging, including late gadolinium enhancement assessment of fibrosis.

54 ed native/postcontrast T1 maps, T2 maps, and late gadolinium enhancement at days 1 and 21 post-MI.

55 The presence of late gadolinium enhancement at magnetic resonance imagin

56 The presence of late gadolinium enhancement at magnetic resonance imagin

57 CMR, including T2-weighted edema imaging and late gadolinium enhancement before coronary angiography.

58 The association of scar on late gadolinium enhancement cardiac magnetic resonance (

59 Scar signal quantification using late gadolinium enhancement cardiac magnetic resonance (

60 diac electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance s

61 nne muscular dystrophy, myocardial damage by late gadolinium enhancement cardiac MRI and preserved ej

62 Late-gadolinium-enhancement cardiac MRI (LGE-MRI) assess

63 d eighteen consecutive patients referred for late gadolinium enhancement-cardiac magnetic resonance a

64 Late gadolinium enhancement-cardiac magnetic resonance i

65 tected by midwall hyperenhancement (MWHE) on late gadolinium enhancement cardiovascular magnetic reso

66 ted the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic reso

67 with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic reso

68 Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic reso

69 extensive) myocardial scarring identified by late gadolinium enhancement cardiovascular magnetic reso

70 DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic reso

71 Cine and late gadolinium enhancement cardiovascular MR and 2-dime

72 Late gadolinium enhancement-cardiovascular magnetic reso

73 Conversely, late gadolinium enhancement CMR should be postponed in t

74 Late gadolinium enhancement CMR was performed in 30 pati

75 Cine and late gadolinium enhancement CMR were performed in 333 co

76 adenosine stress 3D myocardial perfusion and late gadolinium enhancement CMR.

77 The edema volume in late gadolinium enhancement correlated well with edema v

78 Infarct size (late gadolinium enhancement) decreased after CSC infusio

79 Indexed MRI-late gadolinium enhancement-defined infarct size was 18.

80 In individuals without a late gadolinium enhancement-defined myocardial scar (n =

81 d on CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium enhancement detection showed a higher pe

82 segments with intermediate transmurality of late gadolinium enhancement, dobutamine response improve

83 ardial perfusion, microvascular obstruction, late gadolinium enhancement, edema, and intramyocardial

84 demonstrated that (18)F-FDG extent exceeded late gadolinium enhancement extent (33.2+/-16.2% left ve

85 Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were asse

86 Late gadolinium enhancement for replacement fibrosis was

87 t ventricular (LV) volumes and function, and late gadolinium enhancement for the detection of myocard

88 CMR, 98% completed stress CMR, 82% completed late gadolinium enhancement for viability, 94% completed

89 tween higher baseline hs-cTnT categories and late gadolinium enhancement (>/=7.42 ng/L versus <limit

90 rd ratio=2.18 [1.3-3.8]) and the presence of late gadolinium enhancement (hazard ratio=2.2 [1.4-3.6])

91 Late gadolinium enhancement, however, relies on the regi

92 In parallel, late gadolinium enhancement identified the extent of myo

93 Microvascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes

94 Late gadolinium enhancement images were acquired to dete

95 Late gadolinium enhancement images were blindly interpre

96 ng stenosis was removed, and T2-weighted and late-gadolinium-enhancement images were acquired.

97 cardium were identified from postreperfusion late-gadolinium-enhancement images.

98 Late gadolinium enhancement imaging is an established me

99 Late gadolinium enhancement imaging was abnormal in 79 p

100 Quantification of fibrosis from late gadolinium enhancement imaging was incrementally pe

101 dilator first pass myocardial perfusion, and late gadolinium enhancement imaging), transthoracic echo

102 sted of cine, rest first-pass perfusion, and late gadolinium enhancement imaging.

103 magnetic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients,

104 One subject in group 2 had late gadolinium enhancement in a noncoronary distributio

105 with normal LV contractility and absence of late gadolinium enhancement in all but one patient.

106 There was no late gadolinium enhancement in any of the participants b

107 Emerging data suggest a key role for late gadolinium enhancement in detection of left ventric

108 al role for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and nonin

109 cant increase in the frequency of noninfarct late gadolinium enhancement in PA (70%) when compared wi

110 e of cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left vent

111 went CMR at 1.5 T including cine, DENSE, and late gadolinium enhancement in subjects >45 years.

112 ease in early disease stages and complements late gadolinium enhancement in visualization of the regi

113 cardial injury could improve the accuracy of late gadolinium-enhancement in predicting functional rec

114 reported for any mice, and the first use of late-gadolinium-enhancement in a mouse model of congenit

115 Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibro

116 magnetic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular f

117 expansion wave was inversely correlated with late-gadolinium enhancement infarct mass (r=-0.81; P<0.0

118 with a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection f

119 Cardiac magnetic resonance late gadolinium enhancement (LGE) and feature-tracking a

120 rdiac magnetic resonance imaging pericardial late gadolinium enhancement (LGE) and inflammatory bioma

121 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE

122 netic resonance (CMR) protocol incorporating late gadolinium enhancement (LGE) and magnetic resonance

123 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is eme

124 y parameters at diagnosis predict dynamic of late gadolinium enhancement (LGE) as persistent LGE has

125 nd function and tissue characterization with late gadolinium enhancement (LGE) as well as T1 and T2 m

126 y, there are scarce data on the influence of late gadolinium enhancement (LGE) assessed by cardiovasc

127 right ventricular quantitative analysis and late gadolinium enhancement (LGE) assessments and analyz

128 cidence of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic re

129 Late gadolinium enhancement (LGE) border zone on cardiac

130 Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic re

131 cohort studies have evaluated the ability of late gadolinium enhancement (LGE) by cardiac magnetic re

132 Late gadolinium enhancement (LGE) by cardiac MR (CMR) is

133 examined whether the presence and extent of late gadolinium enhancement (LGE) by cardiovascular magn

134 ave reported an inverse relationship between late gadolinium enhancement (LGE) cardiac magnetic reson

135 Late gadolinium enhancement (LGE) cardiovascular magneti

136 We hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magneti

137 We hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magneti

138 Myocardial fibrosis can be visualized by late gadolinium enhancement (LGE) cardiovascular magneti

139 We investigated whether late gadolinium enhancement (LGE) cardiovascular magneti

140 d with cardiovascular magnetic resonance for late gadolinium enhancement (LGE) detection and quantifi

141 Stress CMR with late gadolinium enhancement (LGE) has also shown that MB

142 ent elevation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demonstrated

143 anced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in v

144 role of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been clarified

145 udies have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogeneity on magne

146 n time inversion-recovery (STIR) images, and late gadolinium enhancement (LGE) images were acquired.

147 Although late gadolinium enhancement (LGE) imaging by cardiac mag

148 D) from flow-limiting coronary stenosis, CMR late gadolinium enhancement (LGE) imaging is currently t

149 Late gadolinium enhancement (LGE) imaging overestimates

150 dergoing cardiac magnetic resonance imaging, late gadolinium enhancement (LGE) in 17 patients, and T2

151 dial extracellular volume fraction (ECV) and late gadolinium enhancement (LGE) in children and young

152 nostic significance of left ventricular (LV) late gadolinium enhancement (LGE) in patients with atria

153 23.1 +/- 10.9 years), 25 (28%) had positive late gadolinium enhancement (LGE) in the ventricular myo

154 Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standar

155 as part of a CMR protocol including MPI and late gadolinium enhancement (LGE) is not well establishe

156 anced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is unresolved.

157 as to assess acute ablation injuries seen on late gadolinium enhancement (LGE) magnetic resonance ima

158 Myocardial fibrosis was detected by late gadolinium enhancement (LGE) MRI, and myocardial pe

159 shows that magnetic resonance imaging (MRI) late gadolinium enhancement (LGE) of the coronary vessel

160 and isolated LV subepicardial/midmyocardial late gadolinium enhancement (LGE) on contrast-enhanced c

161 uspected myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 200

162 beyond that achieved by the well-established late gadolinium enhancement (LGE) technique (which detec

163 The presence of late gadolinium enhancement (LGE) yields a hazard ratio

164 yocardial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their ri

165 s) at rest, hyperemia perfusion defect (PD), late gadolinium enhancement (LGE), and inducible WMA wer

166 pathy (HCM) myocardial fibrosis, detected by late gadolinium enhancement (LGE), is associated to a pr

167 tudy of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardiac magnetic reson

168 ibrosis of the myocardium is detectable with late gadolinium enhancement (LGE).

169 ssment of left ventricular (LV) function and late gadolinium enhancement (LGE).

170 ography, and cardiac magnetic resonance with late gadolinium enhancement (LGE); all 3 tests were <24

171 d large transmural (volume of enhancement on late gadolinium enhancement [LGE] images >20%, n = 72) o

172 r-separated imaging, focal fibrosis imaging (late gadolinium enhancement [LGE]), and (1)H magnetic re

173 e, left ventricular function, and myocardial late gadolinium enhancement [LGE]), and metabolic parame

174 3 years) underwent T2-weighted, tagging, and late gadolinium enhancement magnetic resonance imaging a

175 mic microvascular resistance correlated with late-gadolinium enhancement mass (r=0.48; P=0.03) but no

176 entricular ejection fraction, and percentage late-gadolinium enhancement mass were 1.35+/-1.21 microg

177 l free-breathing, motion-corrected, averaged late-gadolinium-enhancement (moco-LGE) cardiovascular MR

178 I guidance, and gap lengths determined using late gadolinium enhancement MR images were correlated wi

179 luded T2-weighted, native T1/T2 mapping, and late gadolinium enhancement MR imaging.

180 We hypothesized that late gadolinium enhancement MRI (LGE-MRI) can identify l

181 lead tip placement through coregistration of late gadolinium enhancement MRI and cardiac computed tom

182 aracterize different areas of enhancement in late gadolinium enhancement MRI done immediately after a

183 o a 3-tesla MRI system where high-resolution late gadolinium enhancement MRI was used to identify the

184 patients receiving CRT underwent preimplant late gadolinium enhancement MRI, postimplant cardiac CT,

185 and gaps up to 1.4 mm were identified using late gadolinium enhancement MRI.

186 uals with clinical cardiovascular disease or late gadolinium enhancement (n = 167), and after replaci

187 ratio), early gadolinium enhancement ratio, late gadolinium enhancement, native T1 relaxation times,

188 as measured in 27 subjects, all of whom were late gadolinium enhancement negative.

189 Most of these patients were late gadolinium enhancement negative.

190 At baseline, a lower extent of late gadolinium enhancement (odds ratio [OR]: 0.67 [95%

191 ction fraction was 51% (+/-17%), and 32% had late gadolinium enhancement on cardiac magnetic resonanc

192 e: 44 years) arrhythmic MVP patients with LV late gadolinium enhancement on cardiac magnetic resonanc

193 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic r

194 e athletes but none of the controls revealed late gadolinium enhancement on cardiovascular magnetic r

195 ted catecholamine levels, RV dilatation, and late gadolinium enhancement on MRI, increased (18)fluoro

196 Diabetics without late gadolinium enhancement or inducible ischemia had a

197 was associated with increased occurrence of late gadolinium enhancement (P=0.004).

198 ich was mainly asymmetrical, and had similar late gadolinium enhancement patterns.

199 LVEF with both imaging modalities and higher late gadolinium enhancement per-patient prevalence as co

200 stic regression analysis after adjusting for late gadolinium enhancement, perfusion, and wall motion

201 All patients with ECG strain had midwall late gadolinium enhancement (positive and negative predi

202 e identified by wall motion abnormalities or late gadolinium-enhancement positivity.

203 In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvemen

204 iac magnetic resonance evidence of regional (late-gadolinium enhancement quantity, 6.4+/-8.0%) and di

205 02) and closely correlated with the areas of late gadolinium enhancement (R 0.98) with a small bias o

206 Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) and T

207 physiological abnormalities colocalized with late gadolinium enhancement scar, indicating a relations

208 dyskinetic area r=-0.49, P<0.0001; and RVOT late gadolinium enhancement score r=-0.33, P=0.01.

209 cumferential strain (Ecc), segmental area of late gadolinium-enhancement (SEE), microvascular obstruc

210 equences, and infarct size was determined by late gadolinium enhancement sequences and creatine kinas

211 Segmental comparison of (18)F-FDG-uptake and late gadolinium enhancement showed substantial overlap (

212 ven after excluding myocardial segments with late gadolinium enhancement, significant relationships b

213 ]; P=0.016) were higher in MVP patients with late gadolinium enhancement than in those without.

214 wall thickness was greater in segments with late gadolinium enhancement than without (20 +/- 6 mm vs

215 quent myocardial fibrosis as demonstrated by late gadolinium enhancement using cardiac magnetic reson

216 identifying focal ventricular fibrosis with late gadolinium enhancement (ventricular late gadolinium

217 xyglucose score was highest in segments with late gadolinium enhancement versus edema only and remote

218 issue was in good agreement with the 6-month late gadolinium enhancement volume (r=0.99) and correlat

219 In addition, late gadolinium enhancement was also assessed.

220 The presence of late gadolinium enhancement was also significantly assoc

221 Late gadolinium enhancement was assessed by using gradie

222 Late gadolinium enhancement was assessed with CMR.

223 gional LS and CS 2DST and 2DTagg to identify late gadolinium enhancement was compared using receiver

224 Myocardial fibrosis by late gadolinium enhancement was detected in 15.8% of the

225 Global subendocardial late gadolinium enhancement was found in 20 amyloid pati

226 Indeed, late gadolinium enhancement was independently associated

227 left ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid

228 Late gadolinium enhancement was present in >60% of overt

229 icular ejection fraction was 61 +/- 12%; and late gadolinium enhancement was present in 29% and ische

230 Myocardial late gadolinium enhancement was present in 4 (27%) of 15

231 Plaque rupture was found in nearly 40% and late gadolinium enhancement was seen in nearly 40%, with

232 te infarcted versus noninfarcted segments by late gadolinium enhancement was similarly good for regio

233 After injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardia

234 eft ventricular dilation and the presence of late gadolinium enhancement were inversely correlated to

235 edian age: 40 years) MVP patients without LV late gadolinium enhancement were investigated by morphof

236 Both ECV and late gadolinium enhancement were more extensive in sarco

237 t model, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for e

238 Regional left ventricular function and late-gadolinium enhancement were assessed by cardiac mag

239 t of patients with SCD (25%) had evidence of late gadolinium enhancement, whereas only 1 patient had

240 ify regional diffuse fibrosis not visible by late gadolinium enhancement, which was associated with i

241 Late gadolinium enhancement with CMR was performed in 90